18.01.2021 • News

Azelis Enters Philippines with APKI and PSSI Buys

Azelis has agreed to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and Phil-Asiatic Supply & Services Inc. (PSSI), entering the Philippine market and significantly strengthening its footprint in Southeast Asia.

The transaction is expected to close within the next three months. Financial terms were not revealed.

Commenting on the acquisition, Terry Del Rosario, managing director of both APKI and PSSI, said: “Azelis and APKI and PSSI have highly complementary business models which will help us diversify our product portfolio significantly. We will leverage Azelis’ strong focus on the food industry in Asia Pacific which will help us expand our presence in this market.”

Azelis said that the Philippine companies’ strong presence in the personal care segment directly benefits from the population’s increasing purchasing power and growing access to premium products. According to the Luxembourg-headquartered multinational distributor, the Philippines has a population of more than 100 million, a rapidly growing economy and a young workforce with a median age of 26 years. The World Bank is forecasting GDP growth in the Philippines of 5.9% in 2021 and 6% in 2022.

This latest move is the third acquisition that Azelis has announced in a little over three weeks. Earlier this month, it said it was buying major stakes in Vietnamese firms MKVN Chemicals and Viet Chemicals Trading and Service, which was preceded in December by an agreement to purchase CW Pacific in Australia.

Author: Elaine Burridge, Freelance Journalist

Azelis is to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and...
Azelis is to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and Phil-Asiatic Supply & Services Inc. (PSSI), entering the Philippine market and significantly strengthening its footprint in Southeast Asia. The deal is expected to close within the next three months. (c) Azelis

Company

Logo:

Azelis Corporate Services NV

12 box 6, Posthofbrug
2600 Antwerpen
Belgium

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read